Baseline characteristics
| Overall (N=157) | |
| Age (years) | 60.61±11.95 |
| <60 (%) | 66 (42.0) |
| ≥60 (%) | 91 (58.0) |
| Gender (male, %) | 109 (69.4) |
| Body weight (kg) | 61.27±9.14 |
| Body height (cm) | 162.10±7.07 |
| BMI (kg/m2) | 23.28±2.93 |
| <18.5 | 5 (3.2) |
| 18.50–23.99 | 85 (54.1) |
| 24–27.99 | 61 (38.9) |
| ≥28 | 6 (3.8) |
| Tumour stage (AJCC) | |
| I | 48 (30.6) |
| II | 31 (19.7) |
| III | 49 (31.2) |
| IV | 29 (18.5) |
| Tissue type | |
| Adenocarcinoma | 124 (79.0) |
| Signet ring cell carcinoma | 7 (4.5) |
| Others | 11 (7.0) |
| Unknown | 15 (9.5) |
| Neoadjuvant (yes, %) | 2 (1.3) |
| Diabetes (yes, %) | 8 (5.1) |
| Laboratory | |
| White cell count (×109/L) | 5.3 (4.5, 6.25) |
| Haemoglobin (g/L) | 126 (109.5, 139.5) |
| Albumin (g/L) | 38.30±4.18 |
| Triglyceride (mmol/L) | 1.18±0.70 |
| Cholesterol (mmol/L) | 3.75±0.86 |
| C reactive protein (mg/L) | 3.2 (2.5, 4.45) |
| CEA (ng/mL) | 1.12 (0.52, 2.22) |
| CA125 (ng/mL) | 7.2 (4.9, 13.55) |
| CA199 (ng/mL) | 10.43 (6.08, 18.96) |
| CA724 (ng/mL) | 1.84 (1.01, 4.15) |
| CA242 (ng/mL) | 9.97±17.86 |
Normally distributed variables are expressed as mean±SD.
Skewed variables are expressed as median (25th percentile, 75th percentile).
AJCC, American Joint Committee on Cancer; BMI, body mass index; CA125, carbohydrate antigen 125; CA199, carbohydrate antigen 199; CA242, carbohydrate antigen 242; CA724, carbohydrate antigen 724; CEA, carcinoembryonic antigen.